You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.
A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.